J. Patrick Elsevier

PTAB Grants Rare Rehearing Due To Insufficient Evidence Of Obviousness

Known Solution To General Problem Provides Sufficient Motivation To Modify Prior Art

Federal Circuit Holds Objective Indicia Must Be Linked To Novel Features

PTAB Grants Motion to Amend Claims, Kind Of

PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent

Claims Of Patent For Treating Anemia With Iron Carbohydrate Complexes And Denies Motion To Amend Claims, PTAB Litigation Blog

Routine Trial-And-Error Approach To Protein Formulation Is Not Sufficient To Establish Obviousness Absent A Reasonable Expectation Of Success In Achieving The Claimed Formulation, PTAB Litigation Blog

PTAB Agrees To Review Patent Claims Covering Dry Eye Ailments

Invalidity Defenses Raised But Not Instituted During IPR Are Not Barred By Statutory Or Judicial Estoppel

PTAB Declines To Institute IPR Proceedings Against Three Biogen TYSABRI® Formulation Patents

Claim Construction Defeats CFAD's Bid To Invalidate Patent On Controlled Release Compositions Of 5-ASA

Federal Circuit Upholds Invalidity Of Prenatal DNA Test Patent Under 35 U.S.C. § 101